XyloCor Therapeutics

Human heart
#Cardiovascular disease #Gene therapy #Phase II trial #XyloCor Therapeutics

XyloCor financing advances one-time cardiovascular gene therapy

XyloCor Therapeutics has completed a $67.5 million Series B financing to support a Phase IIb clinical trial (EXACT‑2) of XC001 (encoberminogene rezmadenovec) in refractory angina.  The trial will use a new non‑surgical method of endocardial administration via a novel injection catheter.   The financing will also fund a Phase II trial… Read More

#Business & Investment #News